BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 109 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2016. The put-call ratio across all filers is 0.42 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,969,337 | +29.3% | 318,665 | +6.3% | 0.00% | +100.0% |
Q1 2024 | $1,522,709 | -13.7% | 299,749 | +1.7% | 0.00% | -50.0% |
Q4 2023 | $1,764,940 | -15.6% | 294,651 | -0.2% | 0.00% | 0.0% |
Q3 2023 | $2,090,956 | -5.4% | 295,335 | -5.9% | 0.00% | 0.0% |
Q2 2023 | $2,209,813 | +85089.4% | 313,894 | +0.9% | 0.00% | -33.3% |
Q1 2023 | $2,594 | -26.8% | 311,069 | +0.8% | 0.00% | -40.0% |
Q4 2022 | $3,542 | -99.9% | 308,531 | +3.2% | 0.01% | -16.7% |
Q3 2022 | $3,768,000 | +27.6% | 299,050 | +7.1% | 0.01% | +50.0% |
Q2 2022 | $2,954,000 | -37.5% | 279,200 | -3.9% | 0.00% | -33.3% |
Q1 2022 | $4,725,000 | +8.9% | 290,620 | -7.2% | 0.01% | +20.0% |
Q4 2021 | $4,339,000 | -2.8% | 313,268 | +0.8% | 0.01% | -16.7% |
Q3 2021 | $4,466,000 | -6.9% | 310,759 | +2.5% | 0.01% | 0.0% |
Q2 2021 | $4,795,000 | +76.9% | 303,310 | +13.8% | 0.01% | +50.0% |
Q1 2021 | $2,710,000 | +21.9% | 266,467 | -10.7% | 0.00% | +33.3% |
Q4 2020 | $2,224,000 | +143.9% | 298,487 | +12.4% | 0.00% | +200.0% |
Q3 2020 | $912,000 | -30.7% | 265,495 | -3.9% | 0.00% | -50.0% |
Q2 2020 | $1,316,000 | +249.1% | 276,249 | +46.4% | 0.00% | +100.0% |
Q1 2020 | $377,000 | -40.6% | 188,708 | +2.5% | 0.00% | 0.0% |
Q4 2019 | $635,000 | +26.5% | 184,169 | +5.2% | 0.00% | 0.0% |
Q3 2019 | $502,000 | -18.0% | 175,062 | +8.4% | 0.00% | 0.0% |
Q2 2019 | $612,000 | -49.7% | 161,431 | +8.0% | 0.00% | -50.0% |
Q1 2019 | $1,217,000 | +0.7% | 149,535 | -0.2% | 0.00% | -33.3% |
Q4 2018 | $1,209,000 | +68.4% | 149,874 | +59.3% | 0.00% | +200.0% |
Q3 2018 | $718,000 | +32.0% | 94,085 | -0.9% | 0.00% | 0.0% |
Q2 2018 | $544,000 | +24.2% | 94,980 | +3.5% | 0.00% | 0.0% |
Q1 2018 | $438,000 | +9.0% | 91,745 | +12.2% | 0.00% | 0.0% |
Q4 2017 | $402,000 | -19.6% | 81,795 | -14.3% | 0.00% | 0.0% |
Q3 2017 | $500,000 | -4.6% | 95,458 | +1.2% | 0.00% | 0.0% |
Q2 2017 | $524,000 | -28.7% | 94,303 | +7.8% | 0.00% | -50.0% |
Q1 2017 | $735,000 | +37.1% | 87,468 | +3.2% | 0.00% | +100.0% |
Q4 2016 | $536,000 | +49.3% | 84,728 | +4.2% | 0.00% | 0.0% |
Q3 2016 | $359,000 | +26.0% | 81,310 | -19.1% | 0.00% | 0.0% |
Q2 2016 | $285,000 | +16.8% | 100,454 | +16.7% | 0.00% | 0.0% |
Q1 2016 | $244,000 | -71.5% | 86,077 | +3.9% | 0.00% | -66.7% |
Q4 2015 | $855,000 | +1.9% | 82,832 | +12.5% | 0.00% | 0.0% |
Q3 2015 | $839,000 | -26.6% | 73,612 | -3.8% | 0.00% | -25.0% |
Q2 2015 | $1,143,000 | +64.2% | 76,534 | -0.7% | 0.00% | +100.0% |
Q1 2015 | $696,000 | -17.1% | 77,074 | +11.6% | 0.00% | 0.0% |
Q4 2014 | $840,000 | +34.0% | 69,084 | +7.7% | 0.00% | 0.0% |
Q3 2014 | $627,000 | -26.1% | 64,155 | -3.6% | 0.00% | 0.0% |
Q2 2014 | $848,000 | – | 66,535 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 3,846,154 | $40,692,000 | 16.07% |
Fairmount Funds Management LLC | 3,343,107 | $35,370,000 | 8.10% |
Kynam Capital Management, LP | 936,563 | $9,909,000 | 2.53% |
Velan Capital Investment Management LP | 225,000 | $2,381,000 | 2.42% |
ORACLE INVESTMENT MANAGEMENT INC | 603,994 | $6,390,000 | 1.94% |
TANG CAPITAL MANAGEMENT LLC | 1,200,000 | $12,696,000 | 1.93% |
MPM BioImpact LLC | 639,089 | $6,762,000 | 1.88% |
Ghost Tree Capital, LLC | 325,000 | $3,439,000 | 1.79% |
Sarissa Capital Management LP | 1,390,790 | $14,715,000 | 1.48% |
Prosight Management, LP | 176,680 | $1,869,000 | 1.47% |